Charles Mather, IV Biography and Net Worth

Director of Hyperion DeFi

Mr. Mather has been a member of our Board of Directors since March 2018. Since October 2019, Mr. Mather has been Managing Director, Equity Capital Markets at Suntrust Robinson Humphrey, Inc. Prior to that, since March 2015, Mr. Mather has been Managing Director, Co-Head of Equity Capital Markets at BTIG, LLC. From December 2009 to February 2015, he was the Head of Private and Alternative Capital and Co-Head of Equity Capital Markets at Janney Montgomery Scott, LLC. Between May 2007 and September 2008, Mr. Mather was the head of the Structured Equity Group at Jefferies Group Inc. Prior to that, Mr. Mather held various senior investment banking positions at Cowen and Company, including as Co- Head of the Private Equity Group. Mr. Mather serves on the board Wentz LLC. Mr. Mather also served on the board of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) until February 2019 and The Finance Company of Pennsylvania until August 2017. Mr. Mather received a B.A. in History from Brown University and an M.B.A. in Finance from The Wharton School at the University of Pennsylvania.

What is Charles E. Mather, IV's net worth?: The estimated net worth of Charles E. Mather, IV is at least $3.85 thousand as of May 26th, 2023. Mr. Mather, IV owns 969 shares of Hyperion DeFi stock worth more than $3,847 as of December 5th. This net worth evaluation does not reflect any other assets that Mr. Mather, IV may own. Learn More about Charles E. Mather, IV's net worth.
How do I contact Charles E. Mather, IV?: The corporate mailing address for Mr. Mather, IV and other Hyperion DeFi executives is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. Hyperion DeFi can also be reached via phone at (917) 289-1117 and via email at [email protected]. Learn More on Charles E. Mather, IV's contact information.
Has Charles E. Mather, IV been buying or selling shares of Hyperion DeFi?: Charles E. Mather, IV has not been actively trading shares of Hyperion DeFi during the last ninety days. Most recently, on Friday, May 26th, Charles E. Iv Mather bought 37 shares of Hyperion DeFi stock. The stock was acquired at an average cost of $199.20 per share, with a total value of $7,370.40. Following the completion of the transaction, the director now directly owns 969 shares of the company's stock, valued at $193,024.80. Learn More on Charles E. Mather, IV's trading history.
Who are Hyperion DeFi's active insiders?: Hyperion DeFi's insider roster includes Stuart Grant (Major Shareholder), Tsontcho Ianchulev (CEO), Kenneth Lee, Jr. (Director), Charles Mather, IV (Director), and Michael Rowe (COO). Learn More on Hyperion DeFi's active insiders.

Charles E. Mather, IV Insider Trading History at Hyperion DeFi

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/26/2023	Buy	37	$199.20	$7,370.40	969
5/18/2022	Buy	87	$162.40	$14,128.80	604
3/31/2022	Buy	50	$249.60	$12,480.00
11/1/2021	Buy	50	$306.40	$15,320.00
5/28/2021	Buy	37	$380.80	$14,089.60	329
9/19/2018	Buy	50	$383.20	$19,160.00

Charles E. Mather, IV Buying and Selling Activity at Hyperion DeFi

Hyperion DeFi Company Overview

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Today's Range

Now: $3.97

$3.50

$4.09

50 Day Range

MA: $6.70

$3.61

$11.83

2 Week Range

Now: $3.97

$0.85

$17.99

Volume

408,169 shs

Average Volume

328,192 shs

Market Capitalization

$32.16 million

P/E Ratio

N/A

Dividend Yield